Health-related quality of life trajectory of treatment-naive patients with Merkel cell carcinoma receiving avelumab

AIM: To evaluate changes in health-related quality of life (HRQoL) in a Phase II trial (NCT02155647) of treatment-naive patients with metastatic Merkel cell carcinoma treated with avelumab (15-month follow-up). MATERIALS & METHODS: Mixed-effect Models for Repeated Measures were applied to HRQoL...

Descripción completa

Detalles Bibliográficos
Autores principales: Bharmal, Murtuza, Nolte, Sandra, Lebbé, Céleste, Mortier, Laurent, Brohl, Andrew S, Fazio, Nicola, Grob, Jean-Jacquez, Pusceddu, Sara, Hanna, Glenn J, Hassel, Jessica C, Kiecker, Felix, Ellers-Lenz, Barbara, Bajars, Marcis, Güzel, Gülseren, Nghiem, Paul, Hunger, Matthias, Schlichting, Michael, Henry-Szatkowski, Mickaël, D'Angelo, Sandra P
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Future Medicine Ltd 2020
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9437770/
https://www.ncbi.nlm.nih.gov/pubmed/32938212
http://dx.doi.org/10.2217/fon-2020-0426
Descripción
Sumario:AIM: To evaluate changes in health-related quality of life (HRQoL) in a Phase II trial (NCT02155647) of treatment-naive patients with metastatic Merkel cell carcinoma treated with avelumab (15-month follow-up). MATERIALS & METHODS: Mixed-effect Models for Repeated Measures were applied to HRQoL data (FACT-M; EQ-5D-5L) to assess changes over time. Clinically derived progression-free survival was compared with HRQoL deterioration-free survival. RESULTS: Overall, we saw relative stability in HRQoL among 116 included patients, with nonprogression associated with statistically and clinically meaningful better HRQoL compared with progressive disease. Deterioration-free survival rates (49–72% at 6 months, 40–58% at 12 months) were consistently higher/better compared with progression-free survival rates (41/31% at 6/12 months). CONCLUSION: These findings show unique longitudinal HRQoL data for treatment-naive metastatic Merkel cell carcinoma patients treated with avelumab. Clinical trial registration: NCT02155647 (ClinicalTrials.gov).

Ejemplares similares